Key Points
- Suvretta Capital Management, L purchased 77,387 shares on Dec. 29 at $13.44 for $1,040,081.28, increasing its stake to 9,700,195 shares (valued at ~$130.37M); this follows a string of recent purchases including a 1,481,481-share buy on Nov. 7 for about $20M.
- Benitec shares trade near $13.49 (50-day MA $13.55, 200-day MA $13.36) with a market cap of ~$456.8M, and analysts carry an average "Moderate Buy" rating with a mean price target of $26.25 (highs up to $32).
- Benitec Biopharma is a clinical-stage biotechnology company developing ddRNAi gene‑silencing therapies, with lead programs targeting chronic hepatitis B and certain ocular conditions.
Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L acquired 16,836 shares of the business's stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average cost of $13.10 per share, with a total value of $220,551.60. Following the transaction, the director directly owned 9,634,395 shares of the company's stock, valued at $126,210,574.50. This trade represents a 0.18% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Suvretta Capital Management, L also recently made the following trade(s):
- On Monday, December 29th, Suvretta Capital Management, L bought 77,387 shares of Benitec Biopharma stock. The stock was purchased at an average cost of $13.44 per share, for a total transaction of $1,040,081.28.
- On Tuesday, December 23rd, Suvretta Capital Management, L bought 50,000 shares of Benitec Biopharma stock. The stock was purchased at an average price of $12.85 per share, with a total value of $642,500.00.
- On Monday, December 22nd, Suvretta Capital Management, L purchased 19,542 shares of Benitec Biopharma stock. The shares were purchased at an average price of $12.08 per share, for a total transaction of $236,067.36.
- On Friday, December 19th, Suvretta Capital Management, L acquired 16,384 shares of Benitec Biopharma stock. The stock was purchased at an average cost of $11.48 per share, for a total transaction of $188,088.32.
- On Thursday, December 18th, Suvretta Capital Management, L acquired 10,215 shares of Benitec Biopharma stock. The shares were purchased at an average price of $11.24 per share, with a total value of $114,816.60.
- On Friday, November 7th, Suvretta Capital Management, L bought 1,481,481 shares of Benitec Biopharma stock. The shares were acquired at an average price of $13.50 per share, with a total value of $19,999,993.50.
Benitec Biopharma Stock Performance
Shares of BNTC stock opened at $13.49 on Tuesday. Benitec Biopharma Limited has a fifty-two week low of $9.70 and a fifty-two week high of $17.15. The stock's fifty day moving average price is $13.55 and its two-hundred day moving average price is $13.36. The company has a market cap of $456.77 million, a PE ratio of -11.15 and a beta of 0.20.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.13. On average, equities analysts predict that Benitec Biopharma Limited will post -1.48 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently weighed in on BNTC. Wall Street Zen upgraded shares of Benitec Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, November 22nd. Oppenheimer restated an "outperform" rating and issued a $29.00 target price (down previously from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. Citizens Jmp boosted their target price on shares of Benitec Biopharma from $20.00 to $22.00 and gave the stock a "market outperform" rating in a research note on Tuesday, November 4th. HC Wainwright set a $32.00 price target on Benitec Biopharma and gave the company a "buy" rating in a research note on Monday, November 24th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Benitec Biopharma presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.25.
Check Out Our Latest Report on Benitec Biopharma
Hedge Funds Weigh In On Benitec Biopharma
Several large investors have recently modified their holdings of the business. Infinitum Asset Management LLC lifted its holdings in shares of Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after purchasing an additional 915,000 shares during the period. Geode Capital Management LLC raised its position in Benitec Biopharma by 77.6% during the 2nd quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company's stock worth $4,859,000 after purchasing an additional 181,391 shares during the last quarter. UBS Group AG lifted its holdings in Benitec Biopharma by 458.8% during the 3rd quarter. UBS Group AG now owns 99,941 shares of the biotechnology company's stock worth $1,402,000 after buying an additional 82,057 shares during the period. Ameriprise Financial Inc. grew its position in shares of Benitec Biopharma by 219.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company's stock valued at $1,286,000 after buying an additional 75,507 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Benitec Biopharma in the 1st quarter valued at about $597,000. Institutional investors own 52.19% of the company's stock.
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
